Icariside I (GH01) is an orally active metabolite of icalin. Icariside I improves estrogen deficiency-induced osteoporosis by simultaneously regulating osteoblast and osteoclast differentiation. Icariside I promotes ATP (HY-B2176) or Nigericin (HY-127019)-induced mtROS production and NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity. Icariside I does not alter the activation of NLRC4 and AIM2 inflammasomes. Icariside I inhibits breast cancer proliferation, apoptosis, invasion, and metastasis by targeting the IL-6/STAT3 pathway. Icariside I is a kynurenine-AhR pathway inhibitor that alleviates cancer by blocking tumor immune escape[1][2][3][4].
Molekulargewicht:
530.52
Reinheit:
99.30
CAS Nummer:
[56725-99-6]
Formel:
C27H30O11
Target-Kategorie:
Apoptosis,Aryl Hydrocarbon Receptor,Bcl-2 Family,Caspase,CDK,IFNAR,JAK,NOD-like Receptor (NLR),PD-1/PD-L1,Reactive Oxygen Species (ROS),STAT
Anwendungsbeschreibung:
MCE Product type: Natural Products
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
